Tianjin Medical University Cancer Institute and Hospital: Esophageal Squamous Cell Carcinoma trials

The registry lists 19 Esophageal Squamous Cell Carcinoma studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 12 are open to participants now and 0 have results posted.

Phase 2 13Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Phase 2
• Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07721103Phase 2
• Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase IINot yet recruitingNCT07686926Phase 2
• Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCRecruitingNCT07457528Phase 2
• A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07272291Phase 2
• Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingNCT07246330Phase 3
• AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT06489197Phase 2
• Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.RecruitingNCT06452602Phase 2
• Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell CarcinomaRecruitingNCT05637268Phase 2
• A Phase II Study of CRT Combined With QL1706 in ESCC PatientsRecruitingNCT05490719Phase 2
• Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT05449483Phase 2
• Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)RecruitingNCT04807673Phase 3
• Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT06241079
• The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell CarcinomaCompletedNCT06241066
• Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.CompletedNCT06190652
• Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05476380Phase 2
• An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 AntibodyStatus unknownNCT04866381Phase 2
• Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)Status unknownNCT04389177Phase 2
• To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing ChemoradiotherapyCompletedNCT04199832